{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"To evaluate the overall response rate achieved with physician's choice selinexor-based combination therapy as measured by International Myeloma Working Group criteria (based on Kumar et al 2016).","groups":[{"description":"* Selinexor 60 mg PO days 1, 8, 15\n* Pomalidomide 4 mg PO on days 1-21\n* Dexamethasone 40 mg PO or IV on days 1, 8, 15, 22\n* 28 day treatment cycles\n\nSelinexor: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).\n\nPomalidomide: Oral Table\n\nDexamethasone: Oral tablet or injection","id":"OG000","title":"Arm 1"},{"description":"Selinexor 80 mg PO days 1, 8, 15 Daratumumab 1,800mg/30,000 units subcutaneous injection on days 1, 8, 15, 22 of cycles 1 and 2, days 1, 15 of cycles 3-6, day 1 of cycles \\>6 Dexamethasone 40 mg PO or IV days 1, 8, 15, 22 28 day treatment cycle Selinexor: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).\n\nDaratumumab: Injection Dexamethasone: Oral tablet or injection","id":"OG001","title":"Arm 2"},{"description":"* Selinexor 80 mg PO days 1, 8, 15\n* Carfilzomib IV infusion 20 mg/m2 cycle 1, day 1, 56 mg/m2 cycle 1 day 8, 15. Cycle 2+ days 1, 8, 15.\n* Dexamethasone 40 mg IV or PO days 1, 8, 15, 22\n* 28 day treatment cycle\n\nSelinexor: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).\n\nCarfilzomib: Injection\n\nDexamethasone: Oral tablet or injection","id":"OG002","title":"Arm 3"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"End of Therapy, on average 10 months","title":"Overall Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}